Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 6, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim results from the first two cohorts of AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic
View HTML
Toggle Summary Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 2, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today notified regulatory agencies, institutional review boards, and investigators that effective immediately it is voluntarily pausing AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the company’s
View HTML
Toggle Summary Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 30, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROANG3-2001, a Phase 2b clinical study of ARO-ANG3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
View HTML
Toggle Summary Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 26, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented additional positive interim 48-week liver biopsy results from the ongoing AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation
View HTML
Toggle Summary Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 25, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented preclinical data on the development of ARO-DUX4, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with facioscapulohumeral
View HTML
Toggle Summary Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 23, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented positive interim results from AROHSD1001, an ongoing Phase 1/2 clinical study of ARO-HSD, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
View HTML
Toggle Summary Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
- Arrowhead to receive $40 million upfront payment - Horizon to receive a worldwide exclusive license for an investigational short interfering RNA (siRNA) therapeutic targeting xanthine dehydrogenase (XDH) PASADENA, Calif. & DUBLIN--(BUSINESS WIRE)--Jun. 21, 2021-- Arrowhead Pharmaceuticals Inc.
View HTML
Toggle Summary Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
- Arrowhead to receive $40 million upfront payment - Horizon to receive a worldwide exclusive license for an investigational short interfering RNA (siRNA) therapeutic targeting xanthine dehydrogenase (XDH) PASADENA, Calif. & DUBLIN--(BUSINESS WIRE)--Jun. 21, 2021-- Arrowhead Pharmaceuticals Inc.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 3, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAPOC3-2001, a Phase 2b clinical study of ARO-APOC3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 2, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Virtual Healthcare Conference – June 1-4, 2021 June 3, 2021 , 2:30 p.m.
View HTML